CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
002898 Sailong Pharmaceutical Group
- 6.26
- +0.29+4.86%
Market Closed Apr 30 15:00 CST
1.10BMarket Cap-30.84P/E (TTM)
6.27High5.93Low99.44KlotVolume5.93Open5.97Pre Close61.04MTurnover9.82%Turnover RatioLossP/E (Static)176.00MShares12.3952wk High2.21P/B633.90MFloat Cap5.7752wk Low6.27Limit Up101.26MShs Float30.73Historical High5.67Limit Down5.70%Amplitude5.77Historical Low0.02Dividend TTM6.14Avg Price48.55KlotAsk0.32%Div YieldTTM100Lot Size50.03KlotBid
Sailong Pharmaceutical Group News
*ST Ceylon: Announcement on the subsidiary obtaining a registration certificate for injectable voriconazole
Sailong Pharmaceutical: Special instructions on the proposed non-distribution of profits in 2024
Cailong Pharmaceutical: Notice of Annual General Meeting of Shareholders
Sailong Pharmaceutical: 2024 Financial Results Report
Sailong Pharmaceutical: Announcement on Delisting Risk Warning and Suspension of the Company\'s Stock Trading
Sailong Pharmaceutical: Explanation of the Board of Directors and Audit Committee on the reasonableness of the company\'s impairment preparations
Sailong Pharmaceutical: Announcement on 2024 Asset Impairment Preparation
Sailong Pharmaceutical: Review Opinions of the Fourth Board of Directors Audit Committee Meeting at its 2nd Meeting in 2025
Sailong Pharmaceutical: Report on the 2024 Performance Evaluation of Accounting Firms and the Audit Committee\'s Performance of Supervisory Duties
Sailong Pharmaceutical: Explanation of the Supervisory Board on the reasonableness of the company\'s impairment preparations
Sailong Pharmaceutical: Third indicative announcement on the risk of delisting risk of the company\'s stock trading
Sailong Pharmaceutical: Second indicative announcement on the risk of delisting risk of the company\'s stock trading
Cailong Pharmaceutical: An indicative announcement on the risk of delisting risk of the company\'s stock transactions
Sailong Pharmaceutical: Announcement on the subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Sailong Pharmaceutical: Announcement on the subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Sailong Pharmaceutical: Announcement on the subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Sailong Pharmaceutical: Announcement on participating in the tenth batch of centralized national drug procurement and planning to win the bid
Sailong Pharmaceutical: Announcement on the subsidiary obtaining a notice of approval for the marketing application of chemical raw materials
Cailong Pharmaceutical: Announcement on the subsidiary obtaining a drug registration certificate for esprolol hydrochloride injection
Cailong Pharmaceutical: Announcement on the subsidiary obtaining a fluorouracil injection drug registration certificate